Lytix Biopharma: NOK 61m Capital Injection - Redeye
Redeye is optimistic about the directed share issue announced last week and a potential subsequent offering. It significantly strengthens the balance sheet.
ANNONS
Redeye is optimistic about the directed share issue announced last week and a potential subsequent offering. It significantly strengthens the balance sheet.